For Immediate Release:
Contact: Kelly Broadway, 202-808-8853
[email protected]
Washington, D.C. – Entering critical steps to enact budget reconciliation, Congress should focus on dismantling the drug price control regime that already exists in the U.S. health care system, such as those enacted by the Biden administration in the Inflation Reduction Act — not reinforce it with a European model. European price controls are controversial because they restrict access to treatment, promoting worse health outcomes that cost more. Replacing efforts to control fraud in Medicaid with controversial price controls will hold up progress on the budget bill and should be rejected by Congress.
The Trump administration has taken important steps to scale back the oversized impact the government has on health care, the most over-regulated sector of our economy. We support the administration’s efforts to make government more efficient to better serve patients and reduce fraud and waste. It is clear we are at the beginning of a significant positive realignment of the role of government in health care.
Congress should look to important portions of the President’s Executive Order that will improve competition and lower the cost of prescription drugs, such as making sure medicines are dispensed at lower cost doctor offices instead of hospitals, improving the out-of-control 340b program, speeding up approval of competing branded and biosimilar products, eliminating the Biden pill penalty and others.